Pitavastatin/valsartan

Drug Profile

Pitavastatin/valsartan

Alternative Names: Livasartan; Valsartan/pitavastatin

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator JW Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Quinolines; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hyperlipidaemia; Hypertension

Most Recent Events

  • 19 Feb 2013 JW Pharmaceutical completes a phase I trial in Hyperlipidaemia and Hypertension (Volunteers) in South Korea (NCT01406431)
  • 19 Feb 2013 JW Pharmaceutical plans a phase I trial for Hyperlipidaemia and Hypertension (In volunteers) in South Korea (NCT01764178)
  • 31 Jul 2011 Phase-I clinical trials in Hyperlipidaemia in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top